Drug profile · INN
bupropion hydrochloride
BUPROPION HYDROCHLORIDE
bupropion hydrochloride (BUPROPION HYDROCHLORIDE) is a dopamine transporter inhibitor. Associated with Axsome Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Drug details — bupropion hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 7
- Programs
- 5
- Data quality
- 0.89
Quick answer
bupropion hydrochloride (BUPROPION HYDROCHLORIDE) is a dopamine transporter inhibitor. Associated with Axsome Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine transporter inhibitor
Primary target: Sodium-dependent dopamine transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
FDA Approves Auvelity: A New Option for MDD
The FDA has approved Auvelity, a new oral antidepressant combining bupropion and dextromethorphan, for the treatment of major depressive disorder (MDD) in adults. Manufactured by Axsome Therapeutics, this approval marks a significant advancement in MDD treatment options.
FDA Approves Auvelity for MDD: A New Antidepressant Option
The FDA has granted approval for Auvelity, a new oral medication for major depressive disorder (MDD) in adults. This approval introduces a novel treatment option with a distinct mechanism of action and a reported rapid onset of therapeutic effect.
Auvelity FDA Approval: New Hope for MDD Patients
The FDA has approved Auvelity, a groundbreaking oral antidepressant from Axsome Therapeutics, marking a significant advancement in treating major depressive disorder (MDD). This approval introduces a novel mechanism of action for patients seeking effective relief.
Auvelity FDA Approval: New MDD Treatment Option
The FDA has approved Auvelity, a new oral treatment for major depressive disorder (MDD) in adults, marking a significant advancement in mental health therapeutics. Manufactured by Axsome Therapeutics, this approval offers a novel option for patients seeking relief from MDD.
Pipeline programs
Related & competitor drugs
Related patents
-
US 12357697
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 12268693
Pharmaceutical compositions comprising a tolfenamic acid
granted -
US 12156914
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 11780805
Carbamoyl phenylalaninol compounds and uses thereof
granted -
US 11129826
Bupropion as a modulator of drug activity
granted -
US 11123344
Bupropion as a modulator of drug activity
granted -
US 6306436
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
expired
Frequently asked questions
What is bupropion hydrochloride?
bupropion hydrochloride (BUPROPION HYDROCHLORIDE) is a dopamine transporter inhibitor. Associated with Axsome Therapeutics. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bupropion hydrochloride?
BUPROPION HYDROCHLORIDE is a marketed brand name for bupropion hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bupropion hydrochloride?
bupropion hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.